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Introduction {#bph14180-sec-0001}
============

The main function of the extracellular matrix (ECM) is to maintain normal architecture and homeostasis in a tissue‐specific manner. During tumour development, the ECM becomes dysregulated and can therefore provide a favourable micro‐environment during all the stages of tumourigenesis (Schaefer *et al.,* [2017](#bph14180-bib-0045){ref-type="ref"}). One of the crucial modulators of ECM structure and function is [decorin](http://www.uniprot.org/uniprot/P07585), an archetypal member of the small leucine‐rich proteoglycan gene family (Gubbiotti *et al.,* [2016](#bph14180-bib-0021){ref-type="ref"}).

Recently, several studies focusing on decorin in tumourigenesis have, together, indicated that decorin is a potent oncosuppressive molecule (Neill *et al.,* [2015b](#bph14180-bib-0039){ref-type="ref"}; Theocharis and Karamanos, [2017](#bph14180-bib-0053){ref-type="ref"}; Schaefer *et al.,* [2017](#bph14180-bib-0045){ref-type="ref"}). Originally, this was observed when mice lacking both decorin and p53 were shown to exhibit a faster rate of tumour growth than p53 null animals, suggesting that the lack of decorin was tumour‐permissive (Iozzo *et al.,* [1999](#bph14180-bib-0023){ref-type="ref"}). Today, we know that in different malignancies such as breast cancer, bladder cancer and colon cancer, the expression of decorin is markedly decreased (Theocharis and Karamanos, [2017](#bph14180-bib-0053){ref-type="ref"}), so that the malignant cells of these carcinomas do not express decorin (Boström *et al.,* [2013](#bph14180-bib-0010){ref-type="ref"}; Sainio *et al.,* [2013](#bph14180-bib-0043){ref-type="ref"}; Nyman *et al.,* [2015](#bph14180-bib-0040){ref-type="ref"}). On the other hand, the delivery of decorin or the induction of its expression in carcinoma cells has been shown to attenuate the malignant behaviour of cells through a variety of mechanisms (Bi and Yang, [2013](#bph14180-bib-0008){ref-type="ref"}; Neill *et al.,* [2016](#bph14180-bib-0037){ref-type="ref"}; Boström *et al.,* [2017](#bph14180-bib-0009){ref-type="ref"}). Because decorin is an extracellular proteoglycan and its regulatory function is mediated *via* paracrine action, it can transmit a distant oncosuppressive effect on cancer cells (Tralhão *et al.,* [2003](#bph14180-bib-0056){ref-type="ref"}).

As such, decorin‐based adjuvant therapies provide a potential option for treatment of various carcinomas in the future. In this review, we will introduce the structural and functional properties of decorin in more detail. We will particularly focus on decorin as an oncosuppressive molecule and summarize its regulatory activity on different cellular functions including autophagy, mitophagy and immunity. We will also discuss representative preclinical studies utilizing decorin‐based therapies in the treatment of cancers, especially epithelial cancers.

Decorin -- structure, interactions and functions {#bph14180-sec-0002}
================================================

Molecular structure of decorin {#bph14180-sec-0003}
------------------------------

Decorin, originally called PG‐II, PG‐40 and PG‐S2, is the prototypic member of the small leucine‐rich proteoglycan gene family. The name decorin is derived from an early finding that decorin can bind to, that is, 'decorate' [collagen type I](https://en.wikipedia.org/wiki/Collagen_type_I) fibres. Decorin is composed of an approximately 40 kDa core protein to which is attached one glycosaminoglycan (GAG) side chain and up to three N‐linked oligosaccharides (Figure [1](#bph14180-fig-0001){ref-type="fig"}). The single unbranched GAG side chain of decorin is either chondroitin sulfate or dermatan sulfate, and it is attached to Ser^4^ in the second domain of the core protein. The GAG of decorin is a heterogenic polymer consisting of chondroitin and/or dermatan sulfate in variable amounts, depending on the tissue type (Seidler and Dreier, [2008](#bph14180-bib-0047){ref-type="ref"}). In chondroitin sulfate, the uronic acid of the repeating disaccharide is D‐glucuronic acid, which in dermatan sulfate is epimerized to L‐iduronic acid. The third domain contains the leucine‐rich repeats (LRRs) typical of the small leucine‐rich proteoglycans such as decorin. This domain gives decorin its arch‐like three‐dimensional structure. The second and the fourth domains of the decorin core protein are rich in cysteine residues with two disulfide bridges on the N‐terminal side and one on the C‐terminal side.

![Schematic structure of decorin. The decorin core protein comprises four domains, shown as I--IV. Domain I is the signal peptide and the propeptide‐containing domain which is cleaved before decorin can be secreted into the ECM. Domain II (rich in cysteine residues) is the domain where the single GAG side‐chain (either chondroitin sulfate or dermatan sulfate) is attached to Ser^4^. Domain III (characteristic of decorin) consists of 12 tandem LRRs and up to three N‐linked oligosaccharides. Similar to domain II, the carboxy terminal domain (domain IV) contains two cysteine residues. There are two disulfide bridges on the N‐terminal side, and one on the C‐terminal side (not shown in figure). Both the LRR domain (domain III) and the single GAG side chain are primarily responsible for decorin\'s multiple interactions with other molecules, the LRR domain being crucial for decorin‐protein interactions. C, cysteine residue.](BPH-176-5-g001){#bph14180-fig-0001}

Interactions and functions of decorin as a whole molecule {#bph14180-sec-0004}
---------------------------------------------------------

Both the core protein of decorin, especially the LRR domain, and the GAG side chain enable decorin to bind and sequester a large number of different molecules. These decorin‐interacting partners encompass versatile molecular categories including ECM macromolecules, growth factors and some of their receptors, cytokines, enzymes, hormones and lipoproteins (Figure [2](#bph14180-fig-0002){ref-type="fig"}) (Yamaguchi *et al.,* [1990](#bph14180-bib-0059){ref-type="ref"}; Bi and Yang, [2013](#bph14180-bib-0008){ref-type="ref"}; Gubbiotti *et al.,* [2016](#bph14180-bib-0021){ref-type="ref"}; Torres *et al.,* [2017](#bph14180-bib-0055){ref-type="ref"}). These interactions form the basis of decorin\'s multifaceted functions.

![Various molecular categories of decorin\'s interactions. The groups are modified from the analysis performed by Gubbiotti *et al*. ([2016](#bph14180-bib-0021){ref-type="ref"}), where they identified decorin‐binding ligands in the literature and in different interaction databases including MatrixDB ([http://matrixdb.univ‐lyon1.fr/](http://matrixdb.univ-lyon1.fr)). Representative examples of proteins in each different category are as follows: intracellular proteins (filamin A, tyrosine 3‐monooxygenase and zinc finger, and BTB domain containing 33); hormones, (anti)‐coagulation factors, immune‐related and carrier proteins (insulin, tissue‐type plasminogen activator, von Willebrand factor and LDL); enzymes (matrix metalloproteinase 2, 3 and 7); membrane proteins (EGF receptors 1, 2 and 4; IGF‐IR; hepatocyte growth factor receptor; and TLRs 2 and 4); growth factors (TGFβ‐1 and ‐2, and FGF‐1, −2, −7 and −8); and ECM proteins, PGs and matricellular proteins (collagens I--VI, perlecan, fibronectin and thrombospondin 1). The X‐axis indicates the number of molecules (n) in each category. For more details of the various categories, see the reference above. PGs, proteoglycans.](BPH-176-5-g002){#bph14180-fig-0002}

Originally, decorin was shown to be involved in collagen fibrillogenesis in corneal stroma, where its presence inhibited fibrillogenesis (Danielson *et al.,* [1997](#bph14180-bib-0013){ref-type="ref"}). Thereafter, decorin and collagen interaction was shown to be crucial for both proper fibril formation and fibril spacing, as discussed above (Danielson *et al.,* [1997](#bph14180-bib-0013){ref-type="ref"}). Moreover, decorin was identified to induce negative feedback regulation on cell growth *via* its capability to bind to and interact with [TGF‐β](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5060) (Yamaguchi *et al.,* [1990](#bph14180-bib-0059){ref-type="ref"}). Interestingly, this interaction with TGF‐β was shown to occur when decorin was bound to collagen. Currently, decorin is known for its multifunctional activities crucially involved in key cellular events, including regulation of cell signalling, migration, proliferation and apoptosis (Neill *et al.,* [2015b](#bph14180-bib-0039){ref-type="ref"}; Gubbiotti *et al.,* [2016](#bph14180-bib-0021){ref-type="ref"}). These topics will be presented in more detail in the later sections in association with oncogenesis.

Decorin is also involved in several physiological processes such as gonad and chondrogenic differentiation, and angiogenesis (Järveläinen *et al.,* [2015](#bph14180-bib-0024){ref-type="ref"}; Gubbiotti *et al.,* [2016](#bph14180-bib-0021){ref-type="ref"}). For example, together with collagen type VI, decorin has a profound positive effect on the pericellular composition and biomechanical behaviour of human mesenchymal stem cells undergoing chondrogenesis (Gubbiotti *et al.,* [2016](#bph14180-bib-0021){ref-type="ref"}). In angiogenesis, the effect of decorin is context‐dependent, excluding tumourigenesis where decorin acts as an anti‐oncogenic molecule (Järveläinen *et al.,* [2015](#bph14180-bib-0024){ref-type="ref"}). Furthermore, evidence exists that it has a regulatory role in postpartum cell differentiation, including myotube (El Shafey *et al.,* [2016](#bph14180-bib-0015){ref-type="ref"}) and nephron progenitor cell differentiation (Fetting *et al.,* [2014](#bph14180-bib-0017){ref-type="ref"}) as well as spermatogenesis (Adam *et al.,* [2012](#bph14180-bib-0001){ref-type="ref"}). In myogenesis, decorin activates the differentiation of myogenic cells into skeletal muscle cells *via* binding and inactivating the mature myostatin in a zinc‐dependent manner (El Shafey *et al.,* [2016](#bph14180-bib-0015){ref-type="ref"}). Myostatin is a member of the TGF‐β superfamily, and it is involved in the regulation of skeletal muscle mass. On the other hand, during kidney development, decorin is able to promote the retention of nephron progenitor cells in an undifferentiated state (Fetting *et al.,* [2014](#bph14180-bib-0017){ref-type="ref"}). Also in spermatogenesis, decorin acts as a negative regulator of testicular function (Adam *et al.,* [2012](#bph14180-bib-0001){ref-type="ref"}). In fact, the testis of a mouse model with inflammation‐associated infertility, as well as testis of infertile men, exhibit significantly increased levels of decorin expression. Subsequently, this increase in the amount of decorin was associated with increased number of [TNF‐α](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1871) -- producing immune cells (Adam *et al.,* [2012](#bph14180-bib-0001){ref-type="ref"}). Regarding intestinal homeostasis, it was shown that decorin expression is vital for the maintenance of cell maturation (Bi *et al.,* [2008](#bph14180-bib-0007){ref-type="ref"}). During tumourigenesis, decorin was further shown to be a regulator of the innate immune system (Merline *et al.,* [2011](#bph14180-bib-0032){ref-type="ref"}; Frey *et al.,* [2013](#bph14180-bib-0018){ref-type="ref"}), autophagy (Torres *et al.,* [2017](#bph14180-bib-0055){ref-type="ref"}) and mitophagy (Buraschi *et al.,* [2017](#bph14180-bib-0011){ref-type="ref"}), as discussed in more detail below. Although most of decorin\'s interactions are mediated *via* its core protein, the GAG side chain is also of great importance (Järvinen and Prince, [2015](#bph14180-bib-0025){ref-type="ref"}; Neill *et al.,* [2016](#bph14180-bib-0037){ref-type="ref"}).

Interactions and functions of the decorin GAG side chain {#bph14180-sec-0005}
--------------------------------------------------------

The GAG side chain has a central function during collagen fibrillogenesis, where it controls the distance between the forming collagen fibrils (Danielson *et al.,* [1997](#bph14180-bib-0013){ref-type="ref"}). This means that if the length of the GAG is reduced, it decreases the distance between collagen fibrils. Regarding binding of decorin to collagen type I in human dermis, age‐related modifications in the GAG can be observed (Li *et al.,* [2013](#bph14180-bib-0030){ref-type="ref"}). Thus, the molecular size of decorin GAG and the amount of total sulfated GAGs are reduced by 40% in aged human skin compared to young skin without any decrease in the amount of decorin core protein (Li *et al.,* [2013](#bph14180-bib-0030){ref-type="ref"}). This may contribute to the skin fragility of elderly people (Danielson *et al.,* [1997](#bph14180-bib-0013){ref-type="ref"}; Li *et al.,* [2013](#bph14180-bib-0030){ref-type="ref"}). Interestingly, for example, in a specific progeroid phenotype of Ehlers‐Danlos syndrome, 30--70% of decorin molecules are produced without GAG chains (Seidler and Dreier, [2008](#bph14180-bib-0047){ref-type="ref"}). Furthermore, the GAG and collagen type I interaction is also essential for the retention of LDL particles in collagen‐rich areas of atherosclerotic plaques (Tannock, [2014](#bph14180-bib-0051){ref-type="ref"}). In other words, decorin has been identified as one of the vascular proteoglycans participating in the 'response to retention' hypothesis of atherosclerosis. This hypothesis provides an established explanation for the initiation of atherosclerosis where vascular proteoglycans interact with apolipoprotein B‐containing lipoproteins resulting in their retention in the vascular wall. As a result, this LDL--proteoglycan interaction has been proposed to represent a novel therapeutic target, particularly in the initiation phase of atherosclerosis (Tannock, [2014](#bph14180-bib-0051){ref-type="ref"}).

Regarding tumourigenesis, the structure of decorin GAG chain may vary depending on the pathological condition. For example, in human colon adenocarcinoma (Theocharis, [2002](#bph14180-bib-0052){ref-type="ref"}) and in gastric carcinoma (Theocharis *et al.,* [2003](#bph14180-bib-0054){ref-type="ref"}), the GAGs are mostly chondroitin sulfate. Additionally, the GAG of decorin can exhibit a variety of post‐translational modifications in cancer (Theocharis, [2002](#bph14180-bib-0052){ref-type="ref"}; Theocharis *et al.,* [2003](#bph14180-bib-0054){ref-type="ref"}; Seidler and Dreier, [2008](#bph14180-bib-0047){ref-type="ref"}). In gastric cancer, the GAG contains markedly increased amounts of non‐sulfated and 6‐sulfated disaccharide units compared to normal gastric mucosa (Theocharis *et al.,* [2003](#bph14180-bib-0054){ref-type="ref"}). Identical results have been reported in pancreatic cancer (Skandalis *et al.,* [2006](#bph14180-bib-0049){ref-type="ref"}). Although decorin core protein is the primary structure in the sequestering of various growth factors, a GAG rich in chondroitin sulfate with specific sulfation patterns can interact with, for example, [fibroblast growth factor 2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4924) (Theocharis and Karamanos, [2017](#bph14180-bib-0053){ref-type="ref"}). Subsequently, this leads to the activation of the [MAPK](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=288&familyType=ENZYME) pathway and to malignant transformation (Theocharis and Karamanos, [2017](#bph14180-bib-0053){ref-type="ref"}). Thus, the post‐translational sulfation patterns act as a critical molecular recognition elements for different growth factors enabling tumour progression.

Decorin and oncosuppression {#bph14180-sec-0006}
---------------------------

Cancer cells are known to create their own micro‐environment which provides tumourigenesis‐promoting surroundings (Neill *et al.,* [2015b](#bph14180-bib-0039){ref-type="ref"}). This is accomplished *via* reciprocal interactions between the cancer cells and the surrounding non‐malignant stromal cells such as normal fibroblasts, activated fibroblasts (myofibroblasts), cancer‐associated fibroblasts, inflammatory cells and various ECM macromolecules. Epithelial cancers (carcinomas) represent the major group of all human cancers. Indeed, the progression of cancer is known to be dependent on the complex interactions between cancer cells and their adjacent stromal cells (Theocharis and Karamanos, [2017](#bph14180-bib-0053){ref-type="ref"}). Regarding carcinomas, the malignant cells completely lack decorin expression (Boström *et al.,* [2013](#bph14180-bib-0010){ref-type="ref"}; Nyman *et al.,* [2015](#bph14180-bib-0040){ref-type="ref"}; Sainio *et al.,* [2013](#bph14180-bib-0043){ref-type="ref"}). However, decorin can be produced by the peritumoral stromal cells, for example, cancer‐associated fibroblasts. Because decorin is a secreted ECM molecule, its regulatory function is mediated primarily *via* paracrine actions (Tralhão *et al.,* [2003](#bph14180-bib-0056){ref-type="ref"}; Buraschi *et al.,* [2012](#bph14180-bib-0012){ref-type="ref"}; Buraschi *et al.,* [2017](#bph14180-bib-0011){ref-type="ref"}).

Decorin as a pan‐receptor tyrosine kinase inhibitor {#bph14180-sec-0007}
---------------------------------------------------

An overview of the regulatory pathways and functions of decorin in cancer is presented in Figure [3](#bph14180-fig-0003){ref-type="fig"}. First of all, decorin acts as a pan‐[receptor tyrosine kinase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=304&familyType=ENZYME) (pan‐[RTK](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=304)) inhibitor (Neill *et al.,* [2016](#bph14180-bib-0037){ref-type="ref"}). Nearly 20 years ago, it was shown that decorin core protein is able to cause generalized growth suppression of neoplastic cells of various histogenic origin *via* up‐regulating p21^WAF‐1^, a potent inhibitor of [cyclin‐dependent kinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=453&familyType=ENZYME), subsequently inducing G1 cell cycle arrest (Santra *et al.,* [1997](#bph14180-bib-0044){ref-type="ref"}). The cell cycle arrest was further coupled with apoptosis, which resulted from the cleavage and subsequent activation of [caspase‐3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1619) after decorin treatment (Neill *et al.,* [2015b](#bph14180-bib-0039){ref-type="ref"}). This mechanism is of particular importance for inhibition of growth and angiogenesis of cancers enriched with EGF receptors ([EGFR/ErbB1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797)), receptors for hepatocyte growth factor ([Met](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815)) and [VEGF receptor 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813&familyId=324&familyType=CATALYTICRECEPTOR) (Neill et al., [2015a](#bph14180-bib-0038){ref-type="ref"}; Neill *et al.,* [2016](#bph14180-bib-0037){ref-type="ref"}). Decorin was also shown to be able to inhibit the activity of [ErbB2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2019) by regulating the amount of active EGRF/ErbB2 dimers (Neill *et al.,* [2015b](#bph14180-bib-0039){ref-type="ref"}). In the CNS, decorin binds directly to and thereby suppresses the activity of [ErbB4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1799&familyId=320&familyType=CATALYTICRECEPTOR)/signal transducer and activator of transcription protein 3 signalling (Minor *et al.,* [2011](#bph14180-bib-0033){ref-type="ref"}). In addition, decorin has the ability to inhibit various other RTKs, including insulin‐like growth factor receptor 1 ([IGF‐IR](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1801)) and [PDGF](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=322) receptor α/β (Neill *et al.,* [2015b](#bph14180-bib-0039){ref-type="ref"}; Neill *et al.,* [2016](#bph14180-bib-0037){ref-type="ref"}).

![Decorin in cancer, based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database ([http://www.genome.jp/kegg‐bin/show_pathway?hsa05205](http://www.genome.jp/kegg-bin/show_pathway?hsa05205)). This pathway map presents representative examples of decorin interactions with various growth factors and their receptors and subsequent signalling pathways. The Figure is published with permission of the copyright holder (Kanehisa *et al.,* [2017](#bph14180-bib-0026){ref-type="ref"}). Decorin has one GAG side chain which can be either chondroitin sulfate (CS) or dermatan sulfate (DS), and both of these possibilities are presented in the figure. Additional abbreviations used in the figure are as follows: AP4, activating enhancer binding protein 4; Casp3, caspase 3; c‐Cbl, E3 ubiquitin‐protein ligase; elF4B; eukaryotic translation initiation factor 4B; HIF 1α, hypoxia‐inducible factor 1‐α; miR‐21, micro‐RNA 21; mTOR, mechanistic target of rapamycin; Myc, Myc proto‐oncogene protein; PDCD4, programmed cell death 4; PDK‐1, pyruvate dehydrogenase kinase 1; S6, S6 kinase; THBS1, thrombospondin 1; TIMP3, tissue inhibitor of metalloproteinase 3.](BPH-176-5-g003){#bph14180-fig-0003}

Mechanistically, decorin as a monomer operates in the tumour stroma by binding different receptor tyrosine kinases, activating their dimerization and inducing transient autophosphorylation (Theocharis and Karamanos, [2017](#bph14180-bib-0053){ref-type="ref"}). This leads to caveolin‐1‐mediated endocytosis of the activated receptor complex and finally to its lysosomal degradation (Neill *et al.,* [2015b](#bph14180-bib-0039){ref-type="ref"}). Interestingly, IGF‐IR seems to represent the only example among the tumour‐associated RTKs, whose binding with decorin does not lead to internalization and destruction of the receptor complex (Morrione *et al.,* [2013](#bph14180-bib-0034){ref-type="ref"}). Instead, decorin binding blocks the activation of IGF‐IR and suppresses its downstream signalling, thus inhibiting cancer cell motility, invasion and proliferation in a context‐dependent manner (Morrione *et al.,* [2013](#bph14180-bib-0034){ref-type="ref"}). Among RTKs, IGF‐IR is known to be an essential mediator of the progression and cellular proliferation of different human cancers, including breast cancer. The action of decorin in transformed cells is very intriguing, because in normal cells, decorin binding to IGF‐IR induces its phosphorylation leading to downstream signalling activation and ultimately receptor degradation (Morrione *et al.,* [2013](#bph14180-bib-0034){ref-type="ref"}; Neill *et al.,* [2015a](#bph14180-bib-0038){ref-type="ref"}). The crosstalk between EGFR and IGF‐IR in oestrogen‐responsive breast cancers is also currently emerging, highlighting the essential role and production of the ECM molecules in the regulation of cancer aggressiveness (Afratis *et al.,* [2017](#bph14180-bib-0002){ref-type="ref"}). Specifically, it appears that the interaction between the [oestradiol receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620) and EGFR/IGF‐IR modulates the expression and localization of various matrix molecules, particularly proteoglycans (Afratis *et al.,* [2017](#bph14180-bib-0002){ref-type="ref"}).

Decorin in autophagy and mitophagy {#bph14180-sec-0008}
----------------------------------

Autophagy has traditionally been regarded as a tumour‐promoting process, allowing prolonged survival for the cancer cells. Nonetheless, it has been shown that at certain stages of tumourigenesis, autophagy can in fact inhibit the progression of tumour growth by protecting the primary stromal cells from cancer‐associated metabolic stress induced by cellular debris and protein aggregates (Goyal *et al.,* [2014](#bph14180-bib-0020){ref-type="ref"}). In a preclinical transcriptomic screening using a triple‐negative orthotopic breast carcinoma model, systemic administration of decorin core protein altered the global gene expression profile of the tumour micro‐environment (Buraschi *et al.,* [2012](#bph14180-bib-0012){ref-type="ref"}). Decorin was also able to reprogramme the tumour stroma in a paracrine fashion, turning it into a less favourable environment for the progression of cancer (Buraschi *et al.,* [2012](#bph14180-bib-0012){ref-type="ref"}). This effect has been linked with the evoked expression of paternally expressed gene 3 (Peg3), an imprinted tumour suppressor gene, which is directly involved in the regulation of endothelial cell autophagy (Torres *et al.,* [2017](#bph14180-bib-0055){ref-type="ref"}). Also a more precise signalling cascade has been revealed in endothelial cells, where decorin, along with other molecules, inhibited anti‐autophagic signalling by suppressing [Akt](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=285)/[mTOR](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109)/p706K activity, simultaneously activating [AMPK](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1540)‐mediated pro‐autophagic signalling pathways (Goyal *et al.,* [2014](#bph14180-bib-0020){ref-type="ref"}). Currently, decorin‐inducible Peg3 has been shown to attenuate angiogenesis *via* thrombospondin 1 expression, which occurs independently of signalling pathways leading to autophagy (Torres *et al.,* [2017](#bph14180-bib-0055){ref-type="ref"}). In addition to acting as an endogenous inhibitor of angiogenesis, thrombospondin 1 is known to variously affect the behaviour of cancer cells including their proliferation, invasion and apoptosis (Torres *et al.,* [2017](#bph14180-bib-0055){ref-type="ref"}).

Mitochondrial autophagy, a process called mitophagy, sequesters and specifically degrades dysfunctional mitochondria before they can cause apoptosis. Interestingly, soluble decorin protein core is able to induce tumour cell mitophagy *via* binding to the Met receptor and thereby inducing mitostatin production (Neill *et al.,* [2015b](#bph14180-bib-0039){ref-type="ref"}; Buraschi *et al.,* [2017](#bph14180-bib-0011){ref-type="ref"}; Schaefer *et al.,* [2017](#bph14180-bib-0045){ref-type="ref"}). The increased amount of mitostatin was further demonstrated to parallel the increased production of [PPARγ coactivator‐1α](http://www.guidetopharmacology.org/GRAC/CoregulatorDisplayForward?coregId=62), and this interaction was shown to lead to stabilized mitostatin mRNA and subsequent accrual of mitostatin protein (Buraschi *et al.,* [2017](#bph14180-bib-0011){ref-type="ref"}). Similar to Peg3, mitostatin was identified as a tumour suppressor gene (Torres *et al.,* [2017](#bph14180-bib-0055){ref-type="ref"}). Furthermore, the decorin‐induced mitostatin‐dependent mitophagy was linked with negative feedback control of [VEGFA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5085) and consequently with the inhibition of tumour angiogenesis (Buraschi *et al.,* [2017](#bph14180-bib-0011){ref-type="ref"}).

Decorin as a modulator of the immune system {#bph14180-sec-0009}
-------------------------------------------

The role of decorin associated with inflammation seems to be versatile and significantly context‐dependent. In normal macrophages, decorin controlled their proliferation by inducing arrest in the G1 phase of cell cycle (Xaus *et al.,* [2001](#bph14180-bib-0057){ref-type="ref"}). This is achieved by inducing the expression of cyclin‐dependent kinase inhibitors p21^Waf‐1^ and p27^Kip‐1^, without any interaction with EGF receptors (Xaus *et al.,* [2001](#bph14180-bib-0057){ref-type="ref"}). Also in inflammatory and fibrotic kidney diseases, decorin suppressed inflammation through its binding and neutralizing of the activity of the pro‐fibrotic factor TGF‐β (Nastase *et al.,* [2017](#bph14180-bib-0036){ref-type="ref"}). Furthermore, decorin interaction with EGFRs and IGF‐IRs was demonstrated to play a beneficial role in the pathogenesis of kidney diseases (Nastase *et al.,* [2017](#bph14180-bib-0036){ref-type="ref"}). Contrasting effect was observed in chronic pancreatitis, where decorin is highly expressed in the stroma by activated pancreatic stellate cells (Köninger *et al.,* [2006](#bph14180-bib-0027){ref-type="ref"}). The increased production of decorin was shown to induce the expression of the chemokine [CCL2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=771), a pro‐inflammatory cytokine in macrophages. As a result, decorin was suggested to link together the extensive desmoplastic reactions and the sustained inflammation present in chronic pancreatitis (Köninger *et al.,* [2006](#bph14180-bib-0027){ref-type="ref"}). In desmoplasia, the tumour mass becomes surrounded by a dense fibrotic tissue rich in ECM macromolecules such as collagen, proteoglycans and hyaluronan. It is typically detected in different cancers, particularly in pancreatic cancer, where it can considerably hinder the targeting of therapeutic drugs to cancer cells (Li *et al.,* [2018](#bph14180-bib-0029){ref-type="ref"}).

The association of inflammation with cancer is still unclear. However, inflammation is considered as an enabling feature of tumourigenesis, for example, in breast cancer (Merline *et al.,* [2011](#bph14180-bib-0032){ref-type="ref"}). Regarding immune responses in tumourigenesis, decorin can regulate two separate molecular interactions. First, decorin binds and inactivates TGF‐β, thus attenuating its tumourigenesis promoting effect (Frey *et al.,* [2013](#bph14180-bib-0018){ref-type="ref"}). Without decorin, TGF‐β would be able to up‐regulate the levels of precursor and mature microRNA‐21 (miR‐21), a pro‐tumorigenic molecule, which is up‐regulated in various cancer cells (Merline *et al.,* [2011](#bph14180-bib-0032){ref-type="ref"}). Secondly, decorin can act as an endogenous ligand for toll‐like receptors ([TLRs](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=316)) 2 and 4 on macrophages (Merline *et al.,* [2011](#bph14180-bib-0032){ref-type="ref"}). This interaction leads to the activation of pathways involving [p38](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=519), MAPK and NF‐κB and subsequently increases the synthesis of known pro‐inflammatory cytokines [IL‐2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4985) and TNF‐α (Merline *et al.,* [2011](#bph14180-bib-0032){ref-type="ref"}; Frey *et al.,* [2013](#bph14180-bib-0018){ref-type="ref"}). Furthermore, decorin binding to TLR2/4 stimulates the production of programmed cell death 4, a translational repressor of various proteins including the anti‐inflammatory cytokine [IL‐10](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4975) in macrophages (Merline *et al.,* [2011](#bph14180-bib-0032){ref-type="ref"}). This cytokine represents one of the most important immunomodulatory cytokines whose signalling pathways connect inflammation and cancer. Thus, by decreasing the production of IL‐10, decorin drives the cytokine profile towards a more pro‐inflammatory phenotype and concomitantly suppresses tumour growth (Merline *et al.,* [2011](#bph14180-bib-0032){ref-type="ref"}).

Therapeutic implications of decorin {#bph14180-sec-0010}
-----------------------------------

Previously, decorin has been reported to possess both synergistic and antagonistic biological interactions with current chemotherapies, such as [carboplatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7624) in ovarian cancer (Nash *et al.,* [1999](#bph14180-bib-0035){ref-type="ref"}) and carboplatin and [gemcitabine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4793) in pancreatic cancer (Köninger *et al.,* [2004](#bph14180-bib-0028){ref-type="ref"}) respectively. Nevertheless, as described above, the established role of decorin as a potent oncosuppressive molecule offers a great potential for decorin‐based adjuvant therapies for epithelial cancers. So far, the therapeutic properties of decorin have been tested *in vitro* and *in vivo* using various delivery systems targeting different cancer cell types (Neill *et al.,* [2016](#bph14180-bib-0037){ref-type="ref"}). The preclinical study settings range from ectopic delivery of decorin core protein to adenoviral (Ad) and oncolytic decorin transduction of cancer cells, and the oncosuppression primarily targets tumour growth and progression. Representative preclinical studies based on the use of decorin in epithelial cancers are shown in Table [1](#bph14180-tbl-0001){ref-type="table"}.

###### 

Preclinical studies in cancers of epithelial origin. Unless otherwise indicated, cell lines are derived from human tumours

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tumour type                                          Cell line                              Delivery system                                      Effect on tumour/tumour cells                                     Reference
  ---------------------------------------------------- -------------------------------------- ---------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------------------------------
  Carcinomas of various origin                         HeLa, WiDr/HT‐29, HCT‐116, A431, PC3   Ectopic expression                                   Decreased growth                                                  (Santra *et al.,* [1997](#bph14180-bib-0044){ref-type="ref"})

  Lung adenocarcinoma                                  A549                                   Ad‐DCN                                               Tumour cell apoptosis and distant DCN anti‐tumour effect          (Tralhão *et al.,* [2003](#bph14180-bib-0056){ref-type="ref"})

  Primary breast carcinoma and pulmonary metastasis    MTLn3 (rat)                            Ad‐DCN                                               Decreased primary growth and elimination of metastases            (Reed *et al.,* [2005](#bph14180-bib-0042){ref-type="ref"})

  Squamous cell carcinoma                              A431                                   Systemic delivery of DCN protein core                Inhibition of tumour growth                                       (Seidler *et al.,* [2006](#bph14180-bib-0048){ref-type="ref"})

  Breast adenocarcinoma                                MTLn3 (rat)                            Systemic delivery of DCN protein core                Inhibition of primary tumour growth and reduction of metastasis   (Goldoni *et al.,* [2008](#bph14180-bib-0019){ref-type="ref"})

  Triple‐negative breast carcinoma                     MDA‐231(GFP+)                          Systemic delivery of DCN protein core                Decreased growth and enhanced apoptosis                           (Buraschi *et al.,* [2012](#bph14180-bib-0012){ref-type="ref"})

  Colorectal carcinoma                                 HCT116                                 Ectopic expression                                   Decreased growth and enhanced apoptosis                           (Bi *et al.,* [2012](#bph14180-bib-0006){ref-type="ref"})

  Bladder cancer                                       RT4, T24                               Ad‐DCN                                               Decreased proliferation                                           (Sainio *et al.,* [2013](#bph14180-bib-0043){ref-type="ref"})

  Cholangiocarcinoma                                   QBC939                                 Ectopic expression                                   Decreased growth and enhanced apoptosis                           (Yu *et al.,* [2014](#bph14180-bib-0062){ref-type="ref"})

  Colorectal adenocarcinoma, colonic carcinoma, and\   CO115, HCT‐116, DLD‐1,\                Ad‐DCN                                               Decrease in colony forming capability                             (Nyman *et al.,* [2015](#bph14180-bib-0040){ref-type="ref"})
  colorectal carcinoma                                 HT‐29, Vaco‐5, LS180, SW620, RKO                                                                                                                              

  Bone metastases of breast carcinoma                  MDA‐MB‐231                             Ad‐DCN and oncolytic Ad‐DCN                          Inhibition of bone metastases progression                         (Yang *et al.,* [2015](#bph14180-bib-0060){ref-type="ref"})

  Bone metastases of prostate cancer                   PC‐3, DU‐145                           Oncolytic Ad‐DCN                                     Inhibition of bone metastases                                     (Xu *et al.,* [2015](#bph14180-bib-0058){ref-type="ref"})

  Lung carcinoma                                       A549                                   Oncolytic Ad‐DCN with single shRNA specific to Met   Increased tumour cell death                                       (Yoon *et al.,* [2016](#bph14180-bib-0061){ref-type="ref"})

  Colorectal adenocarcinoma                            SW480, SW620, CT26 (murine)            Ad‐DCN and oncolytic Ad‐DCN with GM‐CSF              Decreased growth                                                  (Liu *et al.,* [2017](#bph14180-bib-0031){ref-type="ref"})

  Metaplastic breast carcinoma                         Tissue samples                         Ad‐DCN                                               Decreased proliferation and increased apoptosis                   (Boström *et al.,* [2017](#bph14180-bib-0009){ref-type="ref"})

  Pancreatic cancer                                    MIA PaCa‐2                             Oncolytic Ad‐DCN                                     Decreased growth and increased apoptosis                          (Li *et al.,* [2018](#bph14180-bib-0029){ref-type="ref"})

  Breast carcinoma                                     4 T1 (murine)                          Ad‐DCN                                               Decreased progression                                             (Dawoody Nejad *et al.,* [2017](#bph14180-bib-0014){ref-type="ref"})

  Breast carcinoma                                     4 T1 (murine)                          Oncolytic Ad‐DCN with interleukin 12                 Increase in antitumor immune function                             (Oh *et al.,* [2017](#bph14180-bib-0041){ref-type="ref"})
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DCN, decorin; GM‐CSF, granulocyte macrophage colony stimulating factor; shRNA, short hairpin RNA.

According to the [clinicaltrials.gov](http://clinicaltrials.gov) database (<https://clinicaltrials.gov/>), there are currently no clinical trials testing decorin in the treatment of cancer. However, a pilot study using intravitreal injection of decorin in the prevention of proliferative vitreoretinopathy in perforating injuries (NCT02865031) ended in August 2016. However, the results of the study have still not been released. Furthermore, trials using adenoviral vectors and recombinant proteins in various cancers are ongoing, for example, in non‐small cell lung cancer testing the effect of recombinant DNA‐pVAX/L523S (NCT00062907). Overall, modified adenoviruses are the most used viral vectors in clinical trials. They possess several advantages for their use including efficient delivery to both non‐dividing and dividing cells. According to the Gene Therapy Clinical Trials Worldwide (<http://www.abedia.com/wiley/vectors.php>), which is provided by the Journal of Gene Medicine, 20% of all clinical trials using non‐integrating viral or non‐viral vectors involved adenoviruses. The first adenoviral therapy against cancer, Gendicine, was approved for the treatment of head and neck squamous cell carcinoma in the year 2003 in China by the State Food and Drug Administration (SFDA). The gene therapy product is an adenovirus vector carrying the p53 tumour‐suppressor gene. Thereafter, in 2005, the SFDA of China approved Oncorine, for advanced head and neck squamous cell carcinoma, and in October 2015, the US FDA approved Imlygic, for the treatment of melanoma in patients with inoperable tumours. Thus, the development of adenovirus‐based therapies is justified.

Preclinical studies using decorin {#bph14180-sec-0011}
---------------------------------

As mentioned above, TGF‐β is the first growth factor that was shown to be sequestered and its activity inhibited by decorin (Yamaguchi *et al.,* [1990](#bph14180-bib-0059){ref-type="ref"}). Just recently, transduction of pancreatic cancer cells with oncolytic adenoviral decorin vector was shown to suppress the expression of TGF‐β resulting in suppression of growth of cancer cells and induction of their apoptosis (Li *et al.,* [2018](#bph14180-bib-0029){ref-type="ref"}). Additionally, decorin inhibited the expression and accumulation of ECM macromolecules such as collagen types I and III, elastin and [fibronectin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6754), thus attenuating the desmoplastic reaction surrounding pancreatic cancer cells (Li *et al.,* [2018](#bph14180-bib-0029){ref-type="ref"}). This was demonstrated in both orthotopic pancreatic tumours as well as in pancreatic cancer patient‐derived tumour spheroids (Li *et al.,* [2018](#bph14180-bib-0029){ref-type="ref"}). The use of 3D tumour spheroids provide an approach that mimics the tumour micro‐environment of the cancer including its ECM macromolecules and the cellular heterogeneity, more closely than animal models. Regarding breast carcinomas, both systemic delivery of decorin protein core (Goldoni *et al.,* [2008](#bph14180-bib-0019){ref-type="ref"}) and adenoviral transduction (Reed *et al.,* [2005](#bph14180-bib-0042){ref-type="ref"}) decreased the growth of the primary tumour and reduced the progression of metastasis, by inhibiting the ErbB2‐mediated tyrosine kinase cascade and by decreasing the levels of ErbB2 respectively. ErbB2 has been implicated particularly in the progression of breast cancer including the invasion and metastasis of the cancer cells (Reed *et al.,* [2005](#bph14180-bib-0042){ref-type="ref"}). The study performed by Goldoni *et al*. ([2008](#bph14180-bib-0019){ref-type="ref"}) also demonstrated that the effect of decorin on EGFR/ErbB signalling was more efficient than those evoked by an established, low MW, tyrosine kinase inhibitor, [AG879](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4863). Thus, in their experimental setting, decorin prevented the metastatic spreading of cancer cells into lungs, whereas AG879 had no effect (Goldoni *et al.,* [2008](#bph14180-bib-0019){ref-type="ref"}). Adenoviral decorin transduction has also been shown to decrease bone metastasis of breast carcinoma *via* reduction of Met, [β‐catenin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5371) and VEGFA production (Yang *et al.,* [2015](#bph14180-bib-0060){ref-type="ref"}). Furthermore, both Ad‐decorin and oncolytic Ad‐decorin were demonstrated to inhibit bone destruction and reduce tumour burden in breast carcinoma (Yang *et al.,* [2015](#bph14180-bib-0060){ref-type="ref"}). Bone destruction is the result of the interplay between the cancer cells and the bone micro‐environment resulting in release of various cytokines and osteolytic factors. Thus, the potency of decorin to prevent bone metastasis emphasizes its capability to target both the cancer cells and their tumour‐boned micro‐environment (Yang *et al.,* [2015](#bph14180-bib-0060){ref-type="ref"}). Identically, inhibition of the Met‐β‐catenin‐VEGFA axis by oncolytic adenoviral decorin has been achieved in a mouse model of prostate cancer (Xu *et al.,* [2015](#bph14180-bib-0058){ref-type="ref"}). In this particular animal model, which used nude mice with established bone metastases, the systemic delivery of decorin bearing adenovirus resulted in increased overall survival of the mice and significant reduction in the tumour burden. Additionally, a marked inhibition of cancer cachexia, a significant reduction in osteoclast number, osteocalcin levels and hypercalcaemia were detected (Xu *et al.,* [2015](#bph14180-bib-0058){ref-type="ref"}).

In colon carcinoma, the oncosuppressive action of ectopic decorin expression was shown to be mediated *via* induced arrest of cancer cells in G1 phase of cell cycle (Santra *et al.,* [1997](#bph14180-bib-0044){ref-type="ref"}). More precisely, the arrested cell cycle is associated with the induction of p21^WAF‐1^, its subsequent translocation into the nuclei, finally resulting in G1 phase arrest of the cells (Santra *et al.,* [1997](#bph14180-bib-0044){ref-type="ref"}). Regarding colon cancer, the genetic deficiency of decorin has been identified to cause intestinal tumour formation in decorin knockout mice (*DCN−/−*) *via* disruption of intestinal cell maturation (Bi *et al.,* [2008](#bph14180-bib-0007){ref-type="ref"}). These mice exhibit decreased intestinal cell maturation and increased cell proliferation. This was shown to be the result of the down‐regulation of several factors, including p21^WAF‐^1 and p27^Kip‐1^, and E‐cadherin, along with the up‐regulation of the β‐catenin signalling pathway (Bi *et al.,* [2008](#bph14180-bib-0007){ref-type="ref"}). Thereafter, experiments using the same mouse model, together with colon cancer cells transfected with decorin overexpressing plasmids, revealed that the oncosuppressive action of ectopic decorin was associated with the increased stability of E‐cadherin protein (Bi *et al.,* [2012](#bph14180-bib-0006){ref-type="ref"}). Furthermore, an exogenous administration of decorin protein to cholangiocarcinoma cells significantly increased the expression of E‐cadherin (Yu *et al.,* [2014](#bph14180-bib-0062){ref-type="ref"}). E‐cadherin is known for its regulatory action among other things, on epithelial‐mesenchymal transition, cell--cell adhesion and cancer cell metastasis. Other decorin‐induced oncosuppressive regulatory pathways include the promotion of [caspase‐8](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1624) activity in lung carcinoma (Tralhão *et al.,* [2003](#bph14180-bib-0056){ref-type="ref"}). Caspase‐8 is able to both induce cell death directly by activating effector caspases and by initiating other apoptotic cascades. In our own studies, we have achieved oncosuppression in different carcinoma cells using recombinant human decorin cDNA‐based adenoviral vector (Boström *et al.,* [2013](#bph14180-bib-0010){ref-type="ref"}; Sainio *et al.,* [2013](#bph14180-bib-0043){ref-type="ref"}; Nyman *et al.,* [2015](#bph14180-bib-0040){ref-type="ref"}; Boström *et al.,* [2017](#bph14180-bib-0009){ref-type="ref"}). Although the precise mechanisms behind the observed oncosuppression are not yet known, our preliminary results indicate among other things induction and involvement of anti‐tumorigenic microRNAs.

No detectable decorin‐induced toxicity has been found in any of the preclinical studies described above. Currently, modified adenovirus‐based hybrid vectors represent one of the most common tools to deliver genes into cells and organisms. As in Table [1](#bph14180-tbl-0001){ref-type="table"}, most preclinical studies using adenovirus‐based decorin delivery have focused on replication‐defective Ad‐DCN vectors, although some replication‐competent, so‐called oncolytic adenoviral vectors, have also been tested. Compared with non‐replicative adenoviral vectors, the use of oncolytic Ad‐therapy may result in general tissue cytotoxicity if it is not targeted to tumour cells. This is based on the nature of oncolytic viruses, as they replicate within cells and execute the lytic life cycle of viruses, resulting in cellular death. However, the use of oncolytic viruses can improve penetration and viral spread in the cancer tissue due to ECM disruption (Li *et al.,* [2018](#bph14180-bib-0029){ref-type="ref"}). Tissue penetration can be problematic specifically in cancers like pancreatic cancer, where the cancer tissue is often surrounded by a pronounced accumulation of ECM macromolecules (Li *et al.,* [2018](#bph14180-bib-0029){ref-type="ref"}). With the aim of producing cancer cell‐specific virus replication and enhanced antitumor effects, oncolytic adenoviral vectors and decorin have been tested in various combinations with other genes (Yoon *et al.,* [2016](#bph14180-bib-0061){ref-type="ref"}; Oh *et al.,* [2017](#bph14180-bib-0041){ref-type="ref"}; Li *et al.,* [2018](#bph14180-bib-0029){ref-type="ref"}). For example, in an orthotopic breast cancer model, using oncolytic adenoviral decorin‐IL‐12‐vector resulted in enhanced anti‐tumorigenic immune activity in weakly immunogenic BABL/c mice (Oh *et al.,* [2017](#bph14180-bib-0041){ref-type="ref"}). This was achieved with significantly increased expression of TNF‐α, CCL2 and interferon γ with simultaneous decorin‐mediated attenuation of TGF‐β activity (Oh *et al.,* [2017](#bph14180-bib-0041){ref-type="ref"}). Despite these so far promising results, no adenoviral decorin‐based therapy for cancer has been established. Interestingly, a decorin‐based angiogenic blood vessel targeting peptide has been developed for suppression of fibrotic scars during wound healing (Järvinen and Prince, [2015](#bph14180-bib-0025){ref-type="ref"}). This so‐called CAR‐decorin utilizes the capability of decorin to bind and inhibit the activity of TGF‐β, thus reducing tissue fibrosis and enabling tissue regeneration (Järvinen and Prince, [2015](#bph14180-bib-0025){ref-type="ref"}). Nevertheless, this therapy has not yet advanced to clinical trials as an anti‐scarring agent.

Decorin and tumoriangiogenesis {#bph14180-sec-0012}
------------------------------

Angiogenesis, the development of new blood vessel from pre‐existing vessels, is a requirement for tumour progression after cancer has reached a certain size. It is governed by complex regulatory pathways, consisting of both pro‐ and anti‐angiogenic factors. VEGF and its receptors represent an essential example of different molecules regulating the signalling cascades in physiological and pathological angiogenesis (Järveläinen *et al.,* [2015](#bph14180-bib-0024){ref-type="ref"}). During angiogenesis, the role of decorin has been shown to be context‐dependent; in other words, it can exhibit either a pro‐angiogenic or an anti‐angiogenic activity. In the context of tumourigenesis, the role of decorin is anti‐angiogenic. Studies have demonstrated that also peptides derived from decorin possess anti‐angiogenic properties, similar to the mother molecule (Sulochana *et al.,* [2005](#bph14180-bib-0050){ref-type="ref"}; El Shafey *et al.,* [2016](#bph14180-bib-0015){ref-type="ref"}). For instance, a 26‐residue LRR‐5 peptide was demonstrated to prevent angiogenesis *via* any different signalling pathways, including inhibition of VEGF‐activated migration of endothelial cells, and cell attachment to fibronectin (Sulochana *et al.,* [2005](#bph14180-bib-0050){ref-type="ref"}). Such inhibition was shown to be mediated *via* a signalling pathway involving [PI3K](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=781)/Akt and [NO synthase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=253), resulting in reduced production of [NO](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509) in endothelial cells (Fan *et al.,* [2008](#bph14180-bib-0016){ref-type="ref"}). Short decorin‐derived peptides (El Shafey *et al.,* [2016](#bph14180-bib-0015){ref-type="ref"}) and the decorin mimic DS‐SILY (Scott *et al.,* [2013](#bph14180-bib-0046){ref-type="ref"}) also exhibit anti‐angiogenic properties *via* inhibition of the myostatin/Smad signalling pathway and sequestration of [PDGF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5039) respectively. Nevertheless, the true anti‐angiogenic effects of these decorin‐derived peptides and the decorin mimic during angiogenesis are still unclear.

Conclusion and future directions {#bph14180-sec-0013}
--------------------------------

Decorin\'s capability to interact with a variety of molecules including growth factors and their receptors, other ECM macromolecules and cytokines enables decorin to act as a potent oncosuppressive ECM molecule. Indeed, decorin is crucially involved in various signalling pathways regulating tumourigenesis, particularly inhibiting growth, metastasis and angiogenesis of tumours. Recently, it has been demonstrated that decorin is also able to induce autophagy and mitophagy. In light of the promising preclinical studies that have employed decorin or decorin expression to treat cancer, it is rational to further extend this field of research. However, there are still several obstacles including the targeting and successful penetration of the decorin‐based therapy to different malignancies that need to be resolved before the true therapeutic potential of decorin is realised.

Nomenclature of molecular targets {#bph14180-sec-0014}
---------------------------------

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding *et al.,* [2018](#bph14180-bib-0022){ref-type="ref"}), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander *et al.,* [2017a](#bph14180-bib-0003){ref-type="ref"},[b](#bph14180-bib-0004){ref-type="ref"},[c](#bph14180-bib-0005){ref-type="ref"}).
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